CATX Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of -12425.36% compared to Perspective Therapeutics, Inc.'s net margin of -13.47%. Perspective Therapeutics, Inc.'s return on equity of -37.63% beat Accuray, Inc.'s return on equity of -60.6%.

Perspective Therapeutics, Inc. has a consensus price target of $13.3333, signalling upside risk potential of 146.91%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 337.23%. Given that Accuray, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Accuray, Inc. is more attractive than Perspective Therapeutics, Inc..

Perspective Therapeutics, Inc. has a beta of 1.698, which suggesting that the stock is 69.824% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.192, suggesting its more volatile than the S&P 500 by 19.162%.

Perspective Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.

Perspective Therapeutics, Inc. quarterly revenues are $209K, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. Perspective Therapeutics, Inc.'s net income of -$26M is lower than Accuray, Inc.'s net income of -$13.8M. Notably, Perspective Therapeutics, Inc.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics, Inc. is 366.14x versus 0.15x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alphatec Holdings, Inc. has a net margin of -12425.36% compared to Perspective Therapeutics, Inc.'s net margin of -10.21%. Perspective Therapeutics, Inc.'s return on equity of -37.63% beat Alphatec Holdings, Inc.'s return on equity of -1092.5%.

Perspective Therapeutics, Inc. has a consensus price target of $13.3333, signalling upside risk potential of 146.91%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 80.73%. Given that Perspective Therapeutics, Inc. has higher upside potential than Alphatec Holdings, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Alphatec Holdings, Inc..

Perspective Therapeutics, Inc. has a beta of 1.698, which suggesting that the stock is 69.824% more volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.020, suggesting its more volatile than the S&P 500 by 1.994%.

Perspective Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.

Perspective Therapeutics, Inc. quarterly revenues are $209K, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $212.9M. Perspective Therapeutics, Inc.'s net income of -$26M is lower than Alphatec Holdings, Inc.'s net income of -$21.7M. Notably, Perspective Therapeutics, Inc.'s price-to-earnings ratio is -- while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics, Inc. is 366.14x versus 2.67x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of -12425.36% compared to Perspective Therapeutics, Inc.'s net margin of 12.68%. Perspective Therapeutics, Inc.'s return on equity of -37.63% beat Boston Scientific Corp.'s return on equity of 12.55%.

Perspective Therapeutics, Inc. has a consensus price target of $13.3333, signalling upside risk potential of 146.91%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 36.31%. Given that Perspective Therapeutics, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Perspective Therapeutics, Inc. is more attractive than Boston Scientific Corp..

Perspective Therapeutics, Inc. has a beta of 1.698, which suggesting that the stock is 69.824% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.688, suggesting its less volatile than the S&P 500 by 31.155%.

Perspective Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Perspective Therapeutics, Inc. quarterly revenues are $209K, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Perspective Therapeutics, Inc.'s net income of -$26M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Perspective Therapeutics, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 39.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics, Inc. is 366.14x versus 5.72x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -12425.36% compared to Perspective Therapeutics, Inc.'s net margin of -316.61%. Perspective Therapeutics, Inc.'s return on equity of -37.63% beat Plus Therapeutics, Inc.'s return on equity of --.

Perspective Therapeutics, Inc. has a consensus price target of $13.3333, signalling upside risk potential of 146.91%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1716.98%. Given that Plus Therapeutics, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Perspective Therapeutics, Inc..

Perspective Therapeutics, Inc. has a beta of 1.698, which suggesting that the stock is 69.824% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.

Perspective Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Perspective Therapeutics, Inc. quarterly revenues are $209K, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Perspective Therapeutics, Inc.'s net income of -$26M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Perspective Therapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics, Inc. is 366.14x versus 4.85x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.